Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DiagnostykaFRA:7JS +2.29%18 Days Sales Outstanding is 39.56 as of Mar. 2026, which is 9% above its 10-year median of 36.42. GuruFocus rates FRA:7JS with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 202 Medical Diagnostics & Research companies, Diagnostyka ranks better than 81.68% on this metric.
Diagnostyka's average Accounts Receivable for the
three
months ended in Mar. 2026 was €68.4 Mil. Diagnostyka's Revenue for the
three
months ended in Mar. 2026 was €157.8 Mil.
Hence, Diagnostyka's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 39.56.
The historical rank and industry rank for Diagnostyka's Days Sales Outstanding or its related term are showing as below:
FRA:7JS'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 33.26 Med: 36.42 Max: 43.53
Current: 39.34
During the past 5 years, Diagnostyka's highest Days Sales Outstanding was 43.53. The lowest was 33.26. And the median was 36.42.
FRA:7JS's Days Sales Outstanding is ranked better than 81.68% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.82
vs FRA:7JS: 39.34
Diagnostyka's Days Sales Outstanding
increased
from Mar. 2025 (37.58) to Mar. 2026 (39.56).
Diagnostyka (FRA:7JS) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Diagnostyka Days Sales Outstanding Related Terms
Diagnostyka Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Diagnostyka's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7JS vs TMO, DHR, IDXX: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, Diagnostyka's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diagnostyka Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diagnostyka's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Diagnostyka's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diagnostyka (FRA:7JS) has a Days Sales Outstanding of 39.56 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Diagnostyka and its competitors. This is near median its historical median of 36.42. Over the past decade, Diagnostyka's Days Sales Outstanding has ranged from 33.26 to 43.53. According to the industry distribution chart, Diagnostyka ranks #37 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 18.3%.
Is Diagnostyka's Days Sales Outstanding too high?
Diagnostyka's current Days Sales Outstanding of 39.56 is near median its 10-year median of 36.42. Over the past 10 years, this metric has ranged from a low of 33.26 to a high of 43.53. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.82. Diagnostyka's value of 39.56 is 41.7% below this industry median. Based on the distribution chart, Diagnostyka ranks #37 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Diagnostyka has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Diagnostyka's Days Sales Outstanding compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diagnostyka ranks #37 out of 202 companies for Days Sales Outstanding. This places Diagnostyka in the top 18% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 67.82. Diagnostyka's value of 39.56 is 41.7% below this benchmark. Historically, Diagnostyka's own Days Sales Outstanding has ranged from 33.26 to 43.53 over the past decade. While the company's 10-year median is 36.42 vs. the industry median of 67.82, Diagnostyka has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.82, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diagnostyka's current Days Sales Outstanding of 39.56 is 41.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Diagnostyka and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnostyka's current Days Sales Outstanding is 39.56, which is near median its own 10-year median of 36.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnostyka stock overvalued right now?
Diagnostyka (FRA:7JS) has a current Days Sales Outstanding of 39.56. The current Days Sales Outstanding is 39.56, which is near median its 10-year median of 36.42 and 41.7% below the Medical Diagnostics & Research industry median of 67.82. Diagnostyka's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Diagnostyka (FRA:7JS), the current Days Sales Outstanding is 39.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Diagnostyka SA is engaged in providing laboratory diagnostics services in Poland. The company offers comprehensive laboratory services from collecting biological material, through testing, to providing results online.
18GF Score
Get the complete analysis for FRA:7JS
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7JS has been successfully added to your 
